CV Therapeutics submits regadenoson
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CV Therapeutics submits regadenoson: CV Therapeutics and Astellas submit an NDA for their novel cardiac imaging stress agent regadenoson May 14. The application is supported by two Phase III trials, which demonstrated noninferiority compared to Astellas' currently marketed stress agent Adenoscan (adenosine). CVT is highlighting a potential safety benefit for regadenoson over competing stress agents, including the market leader Adenoscan (1Pharmaceutical Approvals Monthly May 2005, p. 12). The filing triggers a $7 million payment from Astellas to CVT; upon approval CVT would receive another $12 million. CVT is also in the process of reshaping its sales force and curtailing R&D expenses to focus on a label expansion of its second-line angina drug Ranexa (ranolazine) and to launch regadenoson in mid-2008 following approval...
You may also be interested in...
CVT Plans Regadenoson NDA Submission As Cardiac Stress Agent For 2006
CV Therapeutics expects to wrap-up two Phase III trials of its selective A2A-adenosine receptor agonist regadenoson (CVT-3146) in the third and fourth quarters, in time for a 2006 NDA submission
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.